Hirotaka Nakayama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hirotaka Nakayama has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Munetaka Masuda
Department of Surgery, Yokohama City University, Yokohama, Japan
7 shared publications - Nobuyasu Suganuma
Kanagawa Cancer Center, Yokohama, Japan
7 shared publications - Yasushi Rino
Department of Surgery, Yokohama City University
7 shared publications - Hiroyuki Iwasaki
Department of Endocrine Surgery, Kanagawa Cancer Center, Kanagawa, Japan
6 shared publications - Haruhiko Yamazaki
Department of Breast and Thyroid Surgery, Yokohama City University Medical Center , Yokohama City, Kanagawa 232-0024
5 shared publications - Katsuhiko Masudo
Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan
5 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.25-0546
Humoral Hypercalcemia of Malignancy Caused by Parathyroid Hormone-Related Protein-Secreting Medullary Thyroid Carcinoma: A Case Report
INTRODUCTION: Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor arising from the parafollicular C cells, accounting for approximately 1.5% of all thyroid cancers. Although calcitonin secreted by the MTC typically lowers calcium levels, serum calcium concentrations usually remain within the normal range due to compensatory parathyroid hormone (PTH) secretion. Hypercalcemia of malignancy is broadly categorized as humoral hypercalcemia of malignancy (HHM), mediated by parathyroid hormone-related protein (PTHrP), or local osteolytic hypercalcemia. We report a rare case of HHM caused by a PTHrP-secreting MTC.CASE PRESENTATION: A 60-year-old woman visited our hospital with weight loss, fatigue, and a large right-sided neck mass. Laboratory tests revealed marked hypercalcemia (16.5 mg/dL), hypophosphatemia, and renal dysfunction. The intact PTH level was within the normal range, whereas the PTHrP level was elevated to 5.7 pmol/L, consistent with HHM. Tumor marker analysis revealed marked increases in carcinoembryonic antigen and calcitonin levels. Imaging studies revealed a large mass in the right thyroid lobe without evidence of regional or distant metastasis. Fine-needle aspiration confirmed the diagnosis of MTC. Genetic testing was negative for rearranged during transfection mutations and multiple endocrine neoplasia 2A, supporting a sporadic form. Hypercalcemia was managed with intravenous hydration (saline solution, 2 L/day for 10 days), elcatonin (80 units/day for 9 days), and a single dose of zoledronic acid. The patient underwent a right thyroid lobectomy. Histopathological analysis confirmed MTC without extra-thyroidal extension or lymph node metastasis (Union for International Cancer Control pT3aN0M0 stageII). Postoperatively, the serum PTHrP levels decreased to normal, and the patient recovered without complications. At the 8-month follow-up, no evidence of recurrence was observed.CONCLUSIONS: Herein, we present a rare case of MTC that caused hypercalcemia via PTHrP production. Although HHM is uncommon in thyroid cancer, the condition can cause severe hypercalcemia requiring prompt diagnosis and treatment. HHM should be considered in patients with thyroid cancer with hypercalcemia, and PTHrP measurement may aid in the diagnosis.
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.25-0546
Open AccessHumoral Hypercalcemia of Malignancy Caused by Parathyroid Hormone-Related Protein-Secreting Medullary Thyroid Carcinoma: A Case Report
INTRODUCTION: Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor arising from the parafollicular C cells, accounting for approximately 1.5% of all thyroid cancers. Although calcitonin secreted by the MTC typically lowers calcium levels, serum calcium concentrations usually remain within the normal range due to compensatory parathyroid hormone (PTH) secretion. Hypercalcemia of malignancy is broadly categorized as humoral hypercalcemia of malignancy (HHM), mediated by parathyroid hormone-related protein (PTHrP), or local osteolytic hypercalcemia. We report a rare case of HHM caused by a PTHrP-secreting MTC.CASE PRESENTATION: A 60-year-old woman visited our hospital with weight loss, fatigue, and a large right-sided neck mass. Laboratory tests revealed marked hypercalcemia (16.5 mg/dL), hypophosphatemia, and renal dysfunction. The intact PTH level was within the normal range, whereas the PTHrP level was elevated to 5.7 pmol/L, consistent with HHM. Tumor marker analysis revealed marked increases in carcinoembryonic antigen and calcitonin levels. Imaging studies revealed a large mass in the right thyroid lobe without evidence of regional or distant metastasis. Fine-needle aspiration confirmed the diagnosis of MTC. Genetic testing was negative for rearranged during transfection mutations and multiple endocrine neoplasia 2A, supporting a sporadic form. Hypercalcemia was managed with intravenous hydration (saline solution, 2 L/day for 10 days), elcatonin (80 units/day for 9 days), and a single dose of zoledronic acid. The patient underwent a right thyroid lobectomy. Histopathological analysis confirmed MTC without extra-thyroidal extension or lymph node metastasis (Union for International Cancer Control pT3aN0M0 stageII). Postoperatively, the serum PTHrP levels decreased to normal, and the patient recovered without complications. At the 8-month follow-up, no evidence of recurrence was observed.CONCLUSIONS: Herein, we present a rare case of MTC that caused hypercalcemia via PTHrP production. Although HHM is uncommon in thyroid cancer, the condition can cause severe hypercalcemia requiring prompt diagnosis and treatment. HHM should be considered in patients with thyroid cancer with hypercalcemia, and PTHrP measurement may aid in the diagnosis.
- Open Access
- 1 September 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 529 (4) , 1195-1200
Membrane type 1 matrix metalloproteinase regulates anaplastic thyroid carcinoma cell growth and invasion into the collagen matrix
- 1 September 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 529 (4) , 1195-1200
Open AccessMembrane type 1 matrix metalloproteinase regulates anaplastic thyroid carcinoma cell growth and invasion into the collagen matrix
- Open Access
Evaluation of the 8th Edition TNM Classification for Anaplastic Thyroid Carcinoma
Background: The tumor–node–metastasis (TNM) classification system to categorized anaplastic thyroid cancer (ATC) was revised. Methods: The revised system was evaluated using a large database of ATC patients. Results: A total of 757 patients were analyzed. The proportion and median overall survival values (OS: months) for each T category were T1 (n = 8, 1.1%, 12.5), T2 (n = 43, 5.7%, 10.9), T3a (n = 117, 15.5%, 5.7), T3b (n = 438, 57.9%, 3.9), and T4 (n = 151, 19.9%, 5.0). The OS of the N0 and N1 patients were 5.9 and 4.3, respectively (log-rank p < 0.01). Sixty-three (58.3%) patients migrated from stage IV A to IV B by revision based on the existence of nodal involvement and 422 patients (55.7%) were stratified into stage IV B, without a worsening of their OS (6.1), leaving 45 patients (5.9%) in stage IV A with fair OS (15.8). The hazard ratios for the survival of the patients of stage IV B compared to stage IV A increased from 1.1 to 2.1 by the revision. No change was made for stage IV C (n = 290, 38.8%, 2.8). Conclusion: The revised TNM system clearly indicated the prognoses of ATC patients by extracting rare patients with fair prognoses as having stage IV A disease and categorized many heterogeneous patients in stage IV B.
Open AccessEvaluation of the 8th Edition TNM Classification for Anaplastic Thyroid Carcinoma
Background: The tumor–node–metastasis (TNM) classification system to categorized anaplastic thyroid cancer (ATC) was revised. Methods: The revised system was evaluated using a large database of ATC patients. Results: A total of 757 patients were analyzed. The proportion and median overall survival values (OS: months) for each T category were T1 (n = 8, 1.1%, 12.5), T2 (n = 43, 5.7%, 10.9), T3a (n = 117, 15.5%, 5.7), T3b (n = 438, 57.9%, 3.9), and T4 (n = 151, 19.9%, 5.0). The OS of the N0 and N1 patients were 5.9 and 4.3, respectively (log-rank p < 0.01). Sixty-three (58.3%) patients migrated from stage IV A to IV B by revision based on the existence of nodal involvement and 422 patients (55.7%) were stratified into stage IV B, without a worsening of their OS (6.1), leaving 45 patients (5.9%) in stage IV A with fair OS (15.8). The hazard ratios for the survival of the patients of stage IV B compared to stage IV A increased from 1.1 to 2.1 by the revision. No change was made for stage IV C (n = 290, 38.8%, 2.8). Conclusion: The revised TNM system clearly indicated the prognoses of ATC patients by extracting rare patients with fair prognoses as having stage IV A disease and categorized many heterogeneous patients in stage IV B.
- 7 February 2020
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (5) , 703-709
Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study
Purpose Fibroblast growth factor receptor 4 (FGFR4) expression has association with tumor malignancy. In thyroid cancers, FGFR4 has been reported to be characteristically expressed in aggressive thyroid tumors, such as anaplastic thyroid carcinoma (ATC). Methods We investigated FGFR4 expression in patients with ATC and analyzed their clinical responses to lenvatinib. Primary tumor samples were obtained from 12 patients with ATC who underwent surgery or core needle biopsy. FGFR4 protein expression in all ATC samples was analyzed via immunohistochemistry, and the treatment efficacy of lenvatinib was evaluated. Results The proportion of FGFR4-positive cells in the samples ranged from 0 to 50%. Four patients had partial responses, and three patients had stable diseases as a best clinical response to lenvatinib. The median PFS durations of patients with none, weak, and moderate intensity were 0.5, 3.2 (95% CI 1.1–not estimable [NE]), and 4.6 (95% CI 1.1–NE) months, respectively (p = 0.003). Conclusions Because FGFR4 was expressed in ATC tissues, the FGFR4 expression might be associated with the treatment efficacy of lenvatinib in a part of ATC patients. To clarify whether FGFR4 can serve as a prognostic or predictive factor for lenvatinib therapy, more cases must be accumulated.
- 7 February 2020
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (5) , 703-709
Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study
Purpose Fibroblast growth factor receptor 4 (FGFR4) expression has association with tumor malignancy. In thyroid cancers, FGFR4 has been reported to be characteristically expressed in aggressive thyroid tumors, such as anaplastic thyroid carcinoma (ATC). Methods We investigated FGFR4 expression in patients with ATC and analyzed their clinical responses to lenvatinib. Primary tumor samples were obtained from 12 patients with ATC who underwent surgery or core needle biopsy. FGFR4 protein expression in all ATC samples was analyzed via immunohistochemistry, and the treatment efficacy of lenvatinib was evaluated. Results The proportion of FGFR4-positive cells in the samples ranged from 0 to 50%. Four patients had partial responses, and three patients had stable diseases as a best clinical response to lenvatinib. The median PFS durations of patients with none, weak, and moderate intensity were 0.5, 3.2 (95% CI 1.1–not estimable [NE]), and 4.6 (95% CI 1.1–NE) months, respectively (p = 0.003). Conclusions Because FGFR4 was expressed in ATC tissues, the FGFR4 expression might be associated with the treatment efficacy of lenvatinib in a part of ATC patients. To clarify whether FGFR4 can serve as a prognostic or predictive factor for lenvatinib therapy, more cases must be accumulated.
- Open Access
- 1 January 2020
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2020 (1) , 4249067
Occult Thyroid Carcinoma without Malignant Thyroid Gland Findings during Preoperative Examination: Report of Three Cases
Occult thyroid carcinoma preceded by clinical manifestations and findings from extrathyroidal tumors is rare. The lack of malignant findings in the thyroid during the preoperative examination makes diagnosis difficult. We encountered a 71‐year‐old man with a primary ectopic thyroid carcinoma causing superior vena cava syndrome. Although no malignant findings were found in the thyroid gland, biopsy of bone metastases led to the diagnosis of thyroid cancer. HE staining of bone metastases revealed nuclear features of papillary carcinoma, and immunostaining was positive for thyroglobulin and PAX‐8. The second case involved an 84‐year‐old man with a mediastinal tumor and suspected thyroid cancer because of high thyroglobulin levels in blood. The pathological tumor finding was papillary thyroid cancer. The last case was that of a 56‐year‐old woman lacking preoperative thyroid examination malignant findings, but with cervical lymph node metastasis. The thyroglobulin level of the lymph node puncture fluid was useful for preoperative diagnosis. We performed total thyroidectomy plus bilateral modified neck dissection. Pathology revealed a 1 mm papillary carcinoma in the left lobe. All of these cases were difficult to diagnose. However, we combined the results of various tests such as radiographic imaging, blood tests, and immunohistological tests to diagnose our patients.
- 1 January 2020
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2020 (1) , 4249067
Open AccessOccult Thyroid Carcinoma without Malignant Thyroid Gland Findings during Preoperative Examination: Report of Three Cases
Occult thyroid carcinoma preceded by clinical manifestations and findings from extrathyroidal tumors is rare. The lack of malignant findings in the thyroid during the preoperative examination makes diagnosis difficult. We encountered a 71‐year‐old man with a primary ectopic thyroid carcinoma causing superior vena cava syndrome. Although no malignant findings were found in the thyroid gland, biopsy of bone metastases led to the diagnosis of thyroid cancer. HE staining of bone metastases revealed nuclear features of papillary carcinoma, and immunostaining was positive for thyroglobulin and PAX‐8. The second case involved an 84‐year‐old man with a mediastinal tumor and suspected thyroid cancer because of high thyroglobulin levels in blood. The pathological tumor finding was papillary thyroid cancer. The last case was that of a 56‐year‐old woman lacking preoperative thyroid examination malignant findings, but with cervical lymph node metastasis. The thyroglobulin level of the lymph node puncture fluid was useful for preoperative diagnosis. We performed total thyroidectomy plus bilateral modified neck dissection. Pathology revealed a 1 mm papillary carcinoma in the left lobe. All of these cases were difficult to diagnose. However, we combined the results of various tests such as radiographic imaging, blood tests, and immunohistological tests to diagnose our patients.
- Open Access
- 11 November 2018
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2018, 1-5
Nephrectomy for Metastatic Kidney Tumor in Patients with Differentiated Thyroid Cancer: A Report of Two Cases
The occurrence of renal tumors originating from thyroid cancer is extremely rare with a few effective treatments for renal metastases. Here, we report the cases of two patients with differentiated thyroid cancer who underwent nephrectomy for a metastatic kidney tumor. Case 1 was a 74-year-old man who was diagnosed with right kidney tumor 10 years after initial surgery for papillary thyroid cancer (PTC). Right nephrectomy was performed, and the pathology was metastatic PTC. Case 2 was a 68-year-old woman who was diagnosed with left kidney tumor 24 years after surgery for follicular thyroid carcinoma (FTC). Left nephrectomy was performed, and the pathology was metastatic FTC. Nephrectomy for single renal metastasis could be considered a treatment option if the patients’ general condition is positive.
- 11 November 2018
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2018, 1-5
Open AccessNephrectomy for Metastatic Kidney Tumor in Patients with Differentiated Thyroid Cancer: A Report of Two Cases
The occurrence of renal tumors originating from thyroid cancer is extremely rare with a few effective treatments for renal metastases. Here, we report the cases of two patients with differentiated thyroid cancer who underwent nephrectomy for a metastatic kidney tumor. Case 1 was a 74-year-old man who was diagnosed with right kidney tumor 10 years after initial surgery for papillary thyroid cancer (PTC). Right nephrectomy was performed, and the pathology was metastatic PTC. Case 2 was a 68-year-old woman who was diagnosed with left kidney tumor 24 years after surgery for follicular thyroid carcinoma (FTC). Left nephrectomy was performed, and the pathology was metastatic FTC. Nephrectomy for single renal metastasis could be considered a treatment option if the patients’ general condition is positive.
- Open Access
- 5 November 2018
- Published by Wiley in Case Reports in Surgery
- Vol. 2018, 1-5
A Large Substernal Goiter that Extended to Both Sides of the Thorax
Most substernal goiters can be managed through the transcervical approach, but a sternotomy is required in some cases. This report is about a large substernal goiter, which was resected via a transcervical and full sternotomy approach. The patient was a 57-year-old female, who visited our hospital for surgical treatment for a large substernal goiter. Computed tomography of the neck and chest revealed that the substernal goiter extended to both sides of the thorax and had compressed the trachea. We performed total thyroidectomy safely via a transcervical and full sternotomy approach. No postoperative complications occurred, except transient hypocalcemia. A histopathological examination did not reveal any malignancy, and the lesion was diagnosed as an adenomatous goiter. Most substernal goiters can be managed through the transcervical approach, but a full sternotomy is required when a substernal goiter extends to both sides of the thorax and/or has a larger diameter than the thoracic inlet or airway constriction is revealed. A full sternotomy provides excellent exposure and can help reduce the risk of complications, such as recurrent laryngeal nerve palsy and injuries to major blood vessels.
- 5 November 2018
- Published by Wiley in Case Reports in Surgery
- Vol. 2018, 1-5
Open AccessA Large Substernal Goiter that Extended to Both Sides of the Thorax
Most substernal goiters can be managed through the transcervical approach, but a sternotomy is required in some cases. This report is about a large substernal goiter, which was resected via a transcervical and full sternotomy approach. The patient was a 57-year-old female, who visited our hospital for surgical treatment for a large substernal goiter. Computed tomography of the neck and chest revealed that the substernal goiter extended to both sides of the thorax and had compressed the trachea. We performed total thyroidectomy safely via a transcervical and full sternotomy approach. No postoperative complications occurred, except transient hypocalcemia. A histopathological examination did not reveal any malignancy, and the lesion was diagnosed as an adenomatous goiter. Most substernal goiters can be managed through the transcervical approach, but a full sternotomy is required when a substernal goiter extends to both sides of the thorax and/or has a larger diameter than the thoracic inlet or airway constriction is revealed. A full sternotomy provides excellent exposure and can help reduce the risk of complications, such as recurrent laryngeal nerve palsy and injuries to major blood vessels.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Tyrosine kinase inhibitor (TKI) treatment outcome of stage IV-C thyroid differentiated cancer (analyzed by lesion evaluation)
Introduction: The standard treatment for differentiated thyroid carcinoma (DTC) with distant metastasis comprises complete total thyroidectomy and lymph node dissection, followed by radioactive iodine (RAI) ablation for metastatic lesions. However, between 2014 and 2015, sorafenib and lenvatinib have been approved for treatment of RAI-refractory advanced thyroid cancer in Japan. We retrospectively analyzed how the treatment results have changed after the approval of tyrosine kinase inhibitor (TKI) treatment. Patients and methods: Among patients currently followed at outpatient clinics, 111 diagnosed with stage IV-C DTC who underwent surgery at our hospitals were included. A total of 48 patients with disease progression and an estimated lesion size ≥15 mm were treated with sorafenib and/or lenvatinib. The approval rate was 43.2%. Lesion evaluation was performed to compare and study these prognoses among 21 patients with lung metastasis, 18 with unresectable local recurrence, and nine with bone metastasis. Results: Treatment results were classified as partial response (PR), stable disease (SD), not evaluable, and progressive disease (PD) in 16 (33.3%), 18 (37.5%), five (10.4%), and nine (18.8%) patients, respectively. The disease control rate (PR + SD) was 34/48 (70.8%) patients. Lesion evaluation showed that the disease control rate for pulmonary metastasis was the best (81.0%) and for bone metastasis (66.7%) and unresectable local recurrence (61.1%) was the worst (Table 1). Table 1 Lesion N PR SD NE PD Death Pulmonary 21 10 7 2 2 4 Local rec. 18 6 5 3 4 6 Bone 9 0 6 0 3 4 Total 48 16 18 5 9 14 Conclusion: Because disease progression of pulmonary metastasis can be identified on a computed tomography image, the timing of TKI treatment was easy to determine and the treatment outcome was satisfactory. However, in some cases, local recurrence involved large blood vessels, or therapy was interrupted due to tumor-skin fistula or bleeding. Eventually, some patients died due to an adverse event (AE) or PD. Some cases of bone metastasis were initially diagnosed with large metastatic lesions, and the treatment outcomes were considered worse. Our results suggested that an appropriate timing of TKI administration and the control of its AEs can improve the prognosis of patients with stage IV-C DTCs with PD.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Tyrosine kinase inhibitor (TKI) treatment outcome of stage IV-C thyroid differentiated cancer (analyzed by lesion evaluation)
Introduction: The standard treatment for differentiated thyroid carcinoma (DTC) with distant metastasis comprises complete total thyroidectomy and lymph node dissection, followed by radioactive iodine (RAI) ablation for metastatic lesions. However, between 2014 and 2015, sorafenib and lenvatinib have been approved for treatment of RAI-refractory advanced thyroid cancer in Japan. We retrospectively analyzed how the treatment results have changed after the approval of tyrosine kinase inhibitor (TKI) treatment. Patients and methods: Among patients currently followed at outpatient clinics, 111 diagnosed with stage IV-C DTC who underwent surgery at our hospitals were included. A total of 48 patients with disease progression and an estimated lesion size ≥15 mm were treated with sorafenib and/or lenvatinib. The approval rate was 43.2%. Lesion evaluation was performed to compare and study these prognoses among 21 patients with lung metastasis, 18 with unresectable local recurrence, and nine with bone metastasis. Results: Treatment results were classified as partial response (PR), stable disease (SD), not evaluable, and progressive disease (PD) in 16 (33.3%), 18 (37.5%), five (10.4%), and nine (18.8%) patients, respectively. The disease control rate (PR + SD) was 34/48 (70.8%) patients. Lesion evaluation showed that the disease control rate for pulmonary metastasis was the best (81.0%) and for bone metastasis (66.7%) and unresectable local recurrence (61.1%) was the worst (Table 1). Table 1 Lesion N PR SD NE PD Death Pulmonary 21 10 7 2 2 4 Local rec. 18 6 5 3 4 6 Bone 9 0 6 0 3 4 Total 48 16 18 5 9 14 Conclusion: Because disease progression of pulmonary metastasis can be identified on a computed tomography image, the timing of TKI treatment was easy to determine and the treatment outcome was satisfactory. However, in some cases, local recurrence involved large blood vessels, or therapy was interrupted due to tumor-skin fistula or bleeding. Eventually, some patients died due to an adverse event (AE) or PD. Some cases of bone metastasis were initially diagnosed with large metastatic lesions, and the treatment outcomes were considered worse. Our results suggested that an appropriate timing of TKI administration and the control of its AEs can improve the prognosis of patients with stage IV-C DTCs with PD.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Expression of VEGFR2 and clinical response of anaplastic thyroid cancer to lenvatinib
Introduction: Angiogenesis is known to play an important role in the development, growth, and metastasis of carcinomas. The vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) are major molecules involved in angiogenesis. The VEGF family includes seven members, respectively named VEGF-A (often simply denoted as VEGF), VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and placental growth factor. The VEGFR is a tyrosine kinase receptor with one to three types and is activated by binding to the VEGF. Among these receptors, the VEGFR2 has an important role in angiogenesis. It is suggested that the expression of VEGF correlates with advanced tumor stage in papillary thyroid cancer (PTC). Anaplastic thyroid cancer (ATC) accounts for 2% of all thyroid cancers but is one of the most lethal neoplasms in humans, with a median survival of 4–6 months. Conventional ATC therapy uses a multimodal approach with radiation therapy and conventional chemotherapy. Some patients survive for a fairly long time after receiving this therapy. A monoclonal antibody against VEGF has been developed for cancer treatment, and its antitumor effect has been reported. The effectiveness of lenvatinib, which mainly inhibits the VEGFR2, has been shown for PTC. Lenvatinib also has significant antitumor effects for ATC and is used in clinical practice. However, few studies report the expression of VEGF or VEGFR in ATC. Here, we studied the expression of VEGFR2 in ATC and the therapeutic effect of lenvatinib on ATC. Materials and methods: Primary tumors were obtained from 12 patients with ATC (five males, seven females; age range, 63–89 years)[Editor1] who underwent surgery or core needle biopsy of a thyroid tumor at the Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Kanagawa, Japan. The protein expression of VEGFR2 in ATC was analyzed using immunohistochemical analysis. Furthermore, the therapeutic effect of lenvatinib was evaluated in seven patients who underwent the same tissue biopsy and lesion evaluation. Result: All 12 patients had no expression of VEGFR2. The therapeutic effect of lenvatinib was classified as a partial response in four patients and as a stable disease in three patients. Conclusion: There was no correlation between the expression of VEGFR2 in ATC tissues and the therapeutic effect of lenvatinib. Further studies are required to improve the overall survival of patients with ATC by investigating clinical predictive factors or new therapeutic target molecules.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Expression of VEGFR2 and clinical response of anaplastic thyroid cancer to lenvatinib
Introduction: Angiogenesis is known to play an important role in the development, growth, and metastasis of carcinomas. The vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) are major molecules involved in angiogenesis. The VEGF family includes seven members, respectively named VEGF-A (often simply denoted as VEGF), VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and placental growth factor. The VEGFR is a tyrosine kinase receptor with one to three types and is activated by binding to the VEGF. Among these receptors, the VEGFR2 has an important role in angiogenesis. It is suggested that the expression of VEGF correlates with advanced tumor stage in papillary thyroid cancer (PTC). Anaplastic thyroid cancer (ATC) accounts for 2% of all thyroid cancers but is one of the most lethal neoplasms in humans, with a median survival of 4–6 months. Conventional ATC therapy uses a multimodal approach with radiation therapy and conventional chemotherapy. Some patients survive for a fairly long time after receiving this therapy. A monoclonal antibody against VEGF has been developed for cancer treatment, and its antitumor effect has been reported. The effectiveness of lenvatinib, which mainly inhibits the VEGFR2, has been shown for PTC. Lenvatinib also has significant antitumor effects for ATC and is used in clinical practice. However, few studies report the expression of VEGF or VEGFR in ATC. Here, we studied the expression of VEGFR2 in ATC and the therapeutic effect of lenvatinib on ATC. Materials and methods: Primary tumors were obtained from 12 patients with ATC (five males, seven females; age range, 63–89 years)[Editor1] who underwent surgery or core needle biopsy of a thyroid tumor at the Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Kanagawa, Japan. The protein expression of VEGFR2 in ATC was analyzed using immunohistochemical analysis. Furthermore, the therapeutic effect of lenvatinib was evaluated in seven patients who underwent the same tissue biopsy and lesion evaluation. Result: All 12 patients had no expression of VEGFR2. The therapeutic effect of lenvatinib was classified as a partial response in four patients and as a stable disease in three patients. Conclusion: There was no correlation between the expression of VEGFR2 in ATC tissues and the therapeutic effect of lenvatinib. Further studies are required to improve the overall survival of patients with ATC by investigating clinical predictive factors or new therapeutic target molecules.
- Open Access
- 27 February 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-14
Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions
In metastatic breast cancer, the status of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), as well as the Ki-67 index sometimes change between primary and metastatic lesions. However, the change in expression levels of enhancer of zeste homolog 2 (EZH2) between primary and metastatic lesions has not been determined in metastatic breast cancer. Ninety-six metastatic breast cancer patients had biopsies or resections of metastatic lesions between September 1990 and February 2014 at the Kanagawa Cancer Center. We evaluated ER, PR, HER2, Ki-67, and EZH2 in primary lesions and their corresponding metastatic lesions using immunohistochemistry. We examined the change in expression of EZH2 between primary and metastatic lesions, the correlation between the expression of EZH2 and the expression of other biomarkers, and the relationship between EZH2 expression and patient outcome in metastatic breast cancer. EZH2 expression was significantly higher in metastatic lesions compared with primary lesions. EZH2 expression was highly correlated with Ki-67 expression in primary and metastatic lesions. High-level expression of EZH2 was associated with poorer disease-free survival (DFS) outcomes in patients with primary lesions (P < 0.001); however, high-level expression of EZH2 was not associated with poorer DFS outcomes in patients with metastatic lesions (P = 0.063). High-level expression of EZH2 was associated with poorer overall survival (OS) postoperatively in patients with primary (P = 0.001) or metastatic lesions (P = 0.005). High-level expression of EZH2 was associated with poorer OS outcomes after recurrence in patients with metastatic lesions (P = 0.014); however, high-level expression of EZH2 was not associated with poorer OS outcomes after recurrence in patients with primary lesions (P = 0.096). High-level expression of EZH2 in metastatic lesions was independently associated with poorer OS outcomes after recurrence. EZH2 expression was significantly increased in metastatic lesions compared with primary lesions. High-level expression of EZH2 in metastatic lesions was associated with poorer OS outcomes after primary surgery and recurrence.
- 27 February 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-14
Open AccessExpression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions
In metastatic breast cancer, the status of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), as well as the Ki-67 index sometimes change between primary and metastatic lesions. However, the change in expression levels of enhancer of zeste homolog 2 (EZH2) between primary and metastatic lesions has not been determined in metastatic breast cancer. Ninety-six metastatic breast cancer patients had biopsies or resections of metastatic lesions between September 1990 and February 2014 at the Kanagawa Cancer Center. We evaluated ER, PR, HER2, Ki-67, and EZH2 in primary lesions and their corresponding metastatic lesions using immunohistochemistry. We examined the change in expression of EZH2 between primary and metastatic lesions, the correlation between the expression of EZH2 and the expression of other biomarkers, and the relationship between EZH2 expression and patient outcome in metastatic breast cancer. EZH2 expression was significantly higher in metastatic lesions compared with primary lesions. EZH2 expression was highly correlated with Ki-67 expression in primary and metastatic lesions. High-level expression of EZH2 was associated with poorer disease-free survival (DFS) outcomes in patients with primary lesions (P < 0.001); however, high-level expression of EZH2 was not associated with poorer DFS outcomes in patients with metastatic lesions (P = 0.063). High-level expression of EZH2 was associated with poorer overall survival (OS) postoperatively in patients with primary (P = 0.001) or metastatic lesions (P = 0.005). High-level expression of EZH2 was associated with poorer OS outcomes after recurrence in patients with metastatic lesions (P = 0.014); however, high-level expression of EZH2 was not associated with poorer OS outcomes after recurrence in patients with primary lesions (P = 0.096). High-level expression of EZH2 in metastatic lesions was independently associated with poorer OS outcomes after recurrence. EZH2 expression was significantly increased in metastatic lesions compared with primary lesions. High-level expression of EZH2 in metastatic lesions was associated with poorer OS outcomes after primary surgery and recurrence.